Global Synthetic Peptide Vaccine 麻豆原创 Growth 2025-2031

Publication ID:

LPI05252930

Publication Date:

May 9, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Synthetic Peptide Vaccine market size is predicted to grow from US$ 121 million in 2025 to US$ 188 million in 2031; it is expected to grow at a CAGR of 7.6% from 2025 to 2031.
Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development.
Synthetic peptide vaccine is the most ideal and safe new vaccine, and it is also one of the main directions for the development of new vaccines for the prevention and control of infectious diseases and malignant tumors.
Currently, synthetic peptide vaccines for human use are all in the research and development/trial stage, and the only commercially available vaccines are for veterinary use, mainly swine foot-and-mouth disease vaccines.
According to the type, the classification of Synthetic Peptide Vaccine includes FMD Type O, FMD Type O+A, etc. In 2024, FMD Type O Synthetic Peptide Vaccine accounted for a share of 48% in the global Synthetic Peptide Vaccine market.
Synthetic Peptide Vaccine is purchased by Government Procurement or Direct Sales. In Synthetic Peptide Vaccine market, the Government Procurement holds an important share in terms of Application. China is the largest consumption place, with a revenue market share nearly 85%.
The market is highly concentrated. Major manufacturers are United Biomedical, CAHIC, and Xinjiang Tecon. Among them, United Biomedical is the largest manufacturer, with a revenue share of 51%.
The 鈥淪ynthetic Peptide Vaccine Industry Forecast鈥� looks at past sales and reviews total world Synthetic Peptide Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Synthetic Peptide Vaccine sales for 2025 through 2031. With Synthetic Peptide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Synthetic Peptide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Synthetic Peptide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Synthetic Peptide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Synthetic Peptide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Synthetic Peptide Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Synthetic Peptide Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Synthetic Peptide Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
FMD Type O
FMD Type O+A
Others
Segmentation by Application:
Government Procurement
Direct Sales
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
United Biomedical
CAHIC
Xinjiang Tecon
ISA Pharmaceuticals
Lytix Biopharma
Merck
OncoTherapy Science
Circio
Stemline Therapeutics
Treos Bio
Key Questions Addressed in this Report
What is the 10-year outlook for the global Synthetic Peptide Vaccine market?
What factors are driving Synthetic Peptide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Synthetic Peptide Vaccine market opportunities vary by end market size?
How does Synthetic Peptide Vaccine break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Synthetic Peptide Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Synthetic Peptide Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Synthetic Peptide Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Synthetic Peptide Vaccine Segment by Type
2.2.1 FMD Type O
2.2.2 FMD Type O+A
2.2.3 Others
2.3 Synthetic Peptide Vaccine Sales by Type
2.3.1 Global Synthetic Peptide Vaccine Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Synthetic Peptide Vaccine Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Synthetic Peptide Vaccine Sale Price by Type (2020-2025)
2.4 Synthetic Peptide Vaccine Segment by Application
2.4.1 Government Procurement
2.4.2 Direct Sales
2.5 Synthetic Peptide Vaccine Sales by Application
2.5.1 Global Synthetic Peptide Vaccine Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Synthetic Peptide Vaccine Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Synthetic Peptide Vaccine Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Synthetic Peptide Vaccine Breakdown Data by Company
3.1.1 Global Synthetic Peptide Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Synthetic Peptide Vaccine Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Synthetic Peptide Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Synthetic Peptide Vaccine Revenue by Company (2020-2025)
3.2.2 Global Synthetic Peptide Vaccine Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Synthetic Peptide Vaccine Sale Price by Company
3.4 Key Manufacturers Synthetic Peptide Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Synthetic Peptide Vaccine Product Location Distribution
3.4.2 Players Synthetic Peptide Vaccine Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Synthetic Peptide Vaccine by Geographic Region
4.1 World Historic Synthetic Peptide Vaccine 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Synthetic Peptide Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Synthetic Peptide Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Synthetic Peptide Vaccine 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Synthetic Peptide Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Synthetic Peptide Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Synthetic Peptide Vaccine Sales Growth
4.4 APAC Synthetic Peptide Vaccine Sales Growth
4.5 Europe Synthetic Peptide Vaccine Sales Growth
4.6 Middle East & Africa Synthetic Peptide Vaccine Sales Growth
5 Americas
5.1 Americas Synthetic Peptide Vaccine Sales by Country
5.1.1 Americas Synthetic Peptide Vaccine Sales by Country (2020-2025)
5.1.2 Americas Synthetic Peptide Vaccine Revenue by Country (2020-2025)
5.2 Americas Synthetic Peptide Vaccine Sales by Type (2020-2025)
5.3 Americas Synthetic Peptide Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Synthetic Peptide Vaccine Sales by Region
6.1.1 APAC Synthetic Peptide Vaccine Sales by Region (2020-2025)
6.1.2 APAC Synthetic Peptide Vaccine Revenue by Region (2020-2025)
6.2 APAC Synthetic Peptide Vaccine Sales by Type (2020-2025)
6.3 APAC Synthetic Peptide Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Synthetic Peptide Vaccine by Country
7.1.1 Europe Synthetic Peptide Vaccine Sales by Country (2020-2025)
7.1.2 Europe Synthetic Peptide Vaccine Revenue by Country (2020-2025)
7.2 Europe Synthetic Peptide Vaccine Sales by Type (2020-2025)
7.3 Europe Synthetic Peptide Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Synthetic Peptide Vaccine by Country
8.1.1 Middle East & Africa Synthetic Peptide Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Synthetic Peptide Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Synthetic Peptide Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Synthetic Peptide Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Synthetic Peptide Vaccine
10.3 Manufacturing Process Analysis of Synthetic Peptide Vaccine
10.4 Industry Chain Structure of Synthetic Peptide Vaccine
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Synthetic Peptide Vaccine Distributors
11.3 Synthetic Peptide Vaccine Customer
12 World Forecast Review for Synthetic Peptide Vaccine by Geographic Region
12.1 Global Synthetic Peptide Vaccine 麻豆原创 Size Forecast by Region
12.1.1 Global Synthetic Peptide Vaccine Forecast by Region (2026-2031)
12.1.2 Global Synthetic Peptide Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Synthetic Peptide Vaccine Forecast by Type (2026-2031)
12.7 Global Synthetic Peptide Vaccine Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 United Biomedical
13.1.1 United Biomedical Company Information
13.1.2 United Biomedical Synthetic Peptide Vaccine Product Portfolios and Specifications
13.1.3 United Biomedical Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 United Biomedical Main Business Overview
13.1.5 United Biomedical Latest Developments
13.2 CAHIC
13.2.1 CAHIC Company Information
13.2.2 CAHIC Synthetic Peptide Vaccine Product Portfolios and Specifications
13.2.3 CAHIC Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 CAHIC Main Business Overview
13.2.5 CAHIC Latest Developments
13.3 Xinjiang Tecon
13.3.1 Xinjiang Tecon Company Information
13.3.2 Xinjiang Tecon Synthetic Peptide Vaccine Product Portfolios and Specifications
13.3.3 Xinjiang Tecon Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Xinjiang Tecon Main Business Overview
13.3.5 Xinjiang Tecon Latest Developments
13.4 ISA Pharmaceuticals
13.4.1 ISA Pharmaceuticals Company Information
13.4.2 ISA Pharmaceuticals Synthetic Peptide Vaccine Product Portfolios and Specifications
13.4.3 ISA Pharmaceuticals Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 ISA Pharmaceuticals Main Business Overview
13.4.5 ISA Pharmaceuticals Latest Developments
13.5 Lytix Biopharma
13.5.1 Lytix Biopharma Company Information
13.5.2 Lytix Biopharma Synthetic Peptide Vaccine Product Portfolios and Specifications
13.5.3 Lytix Biopharma Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Lytix Biopharma Main Business Overview
13.5.5 Lytix Biopharma Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Synthetic Peptide Vaccine Product Portfolios and Specifications
13.6.3 Merck Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 OncoTherapy Science
13.7.1 OncoTherapy Science Company Information
13.7.2 OncoTherapy Science Synthetic Peptide Vaccine Product Portfolios and Specifications
13.7.3 OncoTherapy Science Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 OncoTherapy Science Main Business Overview
13.7.5 OncoTherapy Science Latest Developments
13.8 Circio
13.8.1 Circio Company Information
13.8.2 Circio Synthetic Peptide Vaccine Product Portfolios and Specifications
13.8.3 Circio Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Circio Main Business Overview
13.8.5 Circio Latest Developments
13.9 Stemline Therapeutics
13.9.1 Stemline Therapeutics Company Information
13.9.2 Stemline Therapeutics Synthetic Peptide Vaccine Product Portfolios and Specifications
13.9.3 Stemline Therapeutics Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Stemline Therapeutics Main Business Overview
13.9.5 Stemline Therapeutics Latest Developments
13.10 Treos Bio
13.10.1 Treos Bio Company Information
13.10.2 Treos Bio Synthetic Peptide Vaccine Product Portfolios and Specifications
13.10.3 Treos Bio Synthetic Peptide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Treos Bio Main Business Overview
13.10.5 Treos Bio Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.